{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:20:53Z","timestamp":1794957653712,"version":"4.9.1"},"reference-count":70,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) rather than sulfonylureas is associated with all cause acute pancreatitis and cause specific acute pancreatitis and to characterise temporal risk patterns of the various causes of acute pancreatitis associated with GLP-1RA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Target trial using the electronic healthcare databases of the US Department of Veterans Affairs healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>US Department of Veterans Affairs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>333\u2009687 users of the Veterans Affairs healthcare system with type 2 diabetes initiating GLP-1RA (n=132 551) or sulfonylureas (n=201\u2009136) between 1 January 2017 and 31 December 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Initiation of GLP-1RA or sulfonylureas, and separately, continued use of GLP-1RA or sulfonylureas during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Risks of acute pancreatitis during 12 months\u2019 follow-up including all cause acute pancreatitis and cause specific acute pancreatitis (eg, pancreatitis that is suspected drug induced, alcohol induced, hypertriglyceridaemia associated, biliary, and idiopathic or other cause). The risks were measured through discrete time survival models after application of inverse probability weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In intention-to-treat analyses, participants who initiated GLP-1RAs had similar rates of all cause pancreatitis at one year compared with participants who initiated sulfonylureas (rate difference \u22123.64, 95%\u2009confidence interval (CI) \u221230.76 to 23.48 per 100\u2009000 persons at one year). However, the overall null finding was the net result of countervailing effects across various causes of acute pancreatitis. GLP-1RA was associated with an increased risk of suspected drug induced acute pancreatitis (23.45 (14.27 to 33.85)) and decreased risks of hypertriglyceridaemia associated (\u221216.96 (\u221227.41 to \u22127.34)) and alcohol induced pancreatitis (\u221210.32 (\u221218.12 to \u22123.17)). Similar rates of biliary and idiopathic or other causes of acute pancreatitis were observed in the two groups. In per protocol analyses, drug induced acute pancreatitis attributable to GLP-1RA clustered early (42% of GLP-1RA attributable events over one year of follow-up occurred in the first three months), whereas reductions in alcohol related acute pancreatitis concentrated between months four and six and hypertriglyceridaemia associated acute pancreatitis concentrated between months 10 and 12. Cumulatively, these divergent temporal trends resulted in a net increase in risk of all cause pancreatitis during the first two\u2009months of treatment, with similar monthly risk observed for the remainder of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide cohort, similar rates of all cause acute pancreatitis in GLP-1RA and sulfonylurea users were observed at one year. Increased risk of suspected drug induced pancreatitis during the early period was offset by later reductions in alcohol induced and hypertriglyceridaemia associated acute pancreatitis. Clinicians should counsel patients on early risk while recognising the overall neutral long term effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-002183","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:26:02Z","timestamp":1776875162000},"page":"e002183","source":"Crossref","is-referenced-by-count":4,"title":["GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation"],"prefix":"10.1136","volume":"5","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Center, VA Saint Louis Health Care System, Saint Louis, MO, USA"},{"name":"Veterans Research and Education Foundation of Saint Louis, Saint Louis, MO, USA"},{"name":"Division of Pharmacoepidemiology, Clinical Epidemiology Center, VA Saint Louis Health Care System, Saint Louis, MO, USA"},{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Center, VA Saint Louis Health Care System, Saint Louis, MO, USA"},{"name":"Veterans Research and Education Foundation of Saint Louis, Saint Louis, MO, USA"},{"name":"Division of Pharmacoepidemiology, Clinical Epidemiology Center, VA Saint Louis Health Care System, Saint Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-0434","authenticated-orcid":false,"given":"Ziyad","family":"Al-Aly","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Center, VA Saint Louis Health Care System, Saint Louis, MO, USA"},{"name":"Veterans Research and Education Foundation of Saint Louis, Saint Louis, MO, USA"},{"name":"Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA"},{"name":"Nephrology Section, Medicine Service, VA Saint Louis Health Care System, Saint Louis, MO, USA"},{"name":"Institute for Public Health, Washington University in Saint Louis, Saint Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026042206250814000_5.1.e002183.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"},{"key":"2026042206250814000_5.1.e002183.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.01.010"},{"key":"2026042206250814000_5.1.e002183.3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1461398","article-title":"Pancreatitis and pancreatic cancer signals associated with GLP-1 receptor agonists: A pharmacovigilance analysis of FAERS 2003\u20132023","volume":"15","author":"Guo","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026042206250814000_5.1.e002183.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1344","article-title":"GLP-1 receptor agonists: MHRA to study possible side effects after acute pancreatitis cases","volume":"389","author":"O\u2019Dowd","year":"2025","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.5","unstructured":"Wright K . Concerns Raised Over Pancreatitis Risk from GLP-1 Drugs. European Medical Journal (EMJ) 2025."},{"key":"2026042206250814000_5.1.e002183.6","unstructured":"Medicines, healthcare products regulatory A. GLP-1 receptor agonists (GLP-1RAS) \u2014 yellow card biobank: pancreatitis. 2025. Available: https:\/\/yellowcard.mhra.gov.uk\/biobank-glp-1medicines-pancreatitis"},{"key":"2026042206250814000_5.1.e002183.7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"key":"2026042206250814000_5.1.e002183.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026042206250814000_5.1.e002183.9","unstructured":"Medicines, Healthcare products Regulatory A . If You Take a GLP-1 Medicine and Have Been Hospitalised by Acute Pancreatitis, the Yellow Card Biobank Wants to Hear from You. GOVUK Press Release, 2025."},{"key":"2026042206250814000_5.1.e002183.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"2026042206250814000_5.1.e002183.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2747"},{"key":"2026042206250814000_5.1.e002183.12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"2026042206250814000_5.1.e002183.13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol"},{"key":"2026042206250814000_5.1.e002183.14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","article-title":"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026042206250814000_5.1.e002183.15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026042206250814000_5.1.e002183.16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/dom.13739","article-title":"Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population","volume":"21","author":"Funch","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026042206250814000_5.1.e002183.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2983"},{"key":"2026042206250814000_5.1.e002183.18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026042206250814000_5.1.e002183.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review","volume":"78","author":"Subhani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026042206250814000_5.1.e002183.20","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13776"},{"key":"2026042206250814000_5.1.e002183.21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/dom.16152","article-title":"Glucagon\u2010like peptide\u20101 analogues reduce alcohol intake","volume":"27","author":"O\u2019Farrell","year":"2025","journal-title":"Diabetes Obesity Metabolism"},{"key":"2026042206250814000_5.1.e002183.22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026042206250814000_5.1.e002183.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1614"},{"key":"2026042206250814000_5.1.e002183.24","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2363838"},{"key":"2026042206250814000_5.1.e002183.25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.9734\/ajmah\/2025\/v23i41205","article-title":"\u2018Efficacy of GLP-1 Receptor Agonists\u2019 in Hypertriglyceridemia: A Systemic Review and Meta Analysis","volume":"23","author":"Jahan","year":"2025","journal-title":"Asian J Med Health"},{"key":"2026042206250814000_5.1.e002183.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.014"},{"key":"2026042206250814000_5.1.e002183.27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026042206250814000_5.1.e002183.28","unstructured":"Maynard C . Ascertaining veterans\u2019 vital status: VA data sources for mortality ascertainment and cause of death. Database & Methods Cyberseminar Series 2017."},{"key":"2026042206250814000_5.1.e002183.29","unstructured":"University of wisconsin school of medicine public health. 2013. Available: https:\/\/www.neighborhoodatlas.medicine.wisc.edu"},{"key":"2026042206250814000_5.1.e002183.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1802313"},{"key":"2026042206250814000_5.1.e002183.31","first-page":"876","article-title":"Acute pancreatitis in Helsinki metropolitan area 2016\u20132018\u2014evaluation of a novel severity classification and etiological patterns","volume":"58","author":"Belfrage","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"2026042206250814000_5.1.e002183.32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4274\/jpr.galenos.2022.00018","article-title":"Increasing Diagnosis Rates and the Changing Etiology in Childhood Pancreatitis; Ten Years of a Single-Center Experience in Turkey","volume":"10","author":"\u00c7akar","year":"2023","journal-title":"jpr"},{"key":"2026042206250814000_5.1.e002183.33","doi-asserted-by":"crossref","first-page":"1640267","DOI":"10.3389\/fmed.2025.1640267","article-title":"Etiological shifts and clinical outcomes of acute pancreatitis between urban and rural areas: evidence from a 20-year retrospective database","volume":"12","author":"Cao","year":"2025","journal-title":"Front Med"},{"key":"2026042206250814000_5.1.e002183.34","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/diagnostics12040868","article-title":"Hypertriglyceridaemia-Induced Acute Pancreatitis: A Different Disease Phenotype","volume":"12","author":"Dancu","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026042206250814000_5.1.e002183.35","article-title":"Epidemiology of Biliary Acute Pancreatitis-A Seven-Year Experience of a Large Tertiary Center","volume":"15","author":"Edu","year":"2025","journal-title":"Life (Basel)"},{"key":"2026042206250814000_5.1.e002183.36","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1420590","article-title":"Epidemiology and Etiology of Acute Pancreatitis in Urban and Suburban Areas in Shanghai: A Retrospective Study","volume":"2018","author":"Fan","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"2026042206250814000_5.1.e002183.37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/diagnostics15070882","article-title":"Hypertriglyceridemia-Induced and Alcohol-Induced Acute Pancreatitis\u2014A Severity Comparative Study","volume":"15","author":"Grigore","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026042206250814000_5.1.e002183.38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061299","article-title":"Alcoholic Acute Pancreatitis, a Retrospective Study about Clinical Risk Factors and Outcomes-A Seven-Year Experience of a Large Tertiary Center","volume":"12","author":"G\u0171n\u0219ahin","year":"2024","journal-title":"Biomedicines"},{"key":"2026042206250814000_5.1.e002183.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-018-0821-z","article-title":"Epidemiology and outcomes of acute pancreatitis: a retrospective study of 730 patients from a tertiary center","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"2026042206250814000_5.1.e002183.40","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.12998\/wjcc.v10.i25.8837","article-title":"Hospital admissions from alcohol-related acute pancreatitis: A single UK institution\u2019s experience","volume":"10","author":"Mak","year":"2022","journal-title":"World J Clin Cases"},{"key":"2026042206250814000_5.1.e002183.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-15048-y","article-title":"Combining bedside index of severity in acute pancreatitis (BISAP) and Charlson comorbidity index improves early risk stratification in biliary acute pancreatitis","volume":"15","author":"Prosenz","year":"2025","journal-title":"Sci Rep"},{"key":"2026042206250814000_5.1.e002183.42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/MPA.0000000000001637","article-title":"A 5-Year Retrospective Cohort Study: Epidemiology, Etiology, Severity, and Outcomes of Acute Pancreatitis","volume":"49","author":"Pu","year":"2020","journal-title":"Pancreas"},{"key":"2026042206250814000_5.1.e002183.43","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cam4.5094","article-title":"Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study","volume":"12","author":"Singh","year":"2023","journal-title":"Cancer Med"},{"key":"2026042206250814000_5.1.e002183.44","first-page":"139","article-title":"Epidemiology of Biliary Acute Pancreatitis\u2014A Seven-Year Experience of a Large Tertiary Center","volume":"15","author":"Edu","year":"2025","journal-title":"Life (Basel)"},{"key":"2026042206250814000_5.1.e002183.45","doi-asserted-by":"crossref","unstructured":"Gagnon A-L , Lavoie A , Frigon M-P , et al . A Drug-Induced Acute Pancreatitis Retrospective Study. Can J Gastroenterol Hepatol 2020;1516493\u201393. doi:10.1155\/2020\/1516493","DOI":"10.1155\/2020\/1516493"},{"key":"2026042206250814000_5.1.e002183.46","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/diagnostics15070882","article-title":"Hypertriglyceridemia-Induced and Alcohol-Induced Acute Pancreatitis-A Severity Comparative Study","volume":"15","author":"Grigore","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026042206250814000_5.1.e002183.47","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.pan.2024.08.004","article-title":"Severity and outcome of a first episode of idiopathic acute pancreatitis is not more severe than pancreatitis of other etiologies","volume":"24","author":"Sirtl","year":"2024","journal-title":"Pancreatology"},{"key":"2026042206250814000_5.1.e002183.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072705","article-title":"Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records","volume":"380","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073312","article-title":"Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.50","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1890"},{"key":"2026042206250814000_5.1.e002183.51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026042206250814000_5.1.e002183.52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1473-3099(24)00831-4","article-title":"Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans","volume":"25","author":"Cai","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026042206250814000_5.1.e002183.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403211"},{"key":"2026042206250814000_5.1.e002183.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2510226"},{"key":"2026042206250814000_5.1.e002183.55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","article-title":"High-dimensional characterization of post-acute sequelae of COVID-19","volume":"594","author":"Al-Aly","year":"2021","journal-title":"Nature New Biol"},{"key":"2026042206250814000_5.1.e002183.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02521-2"},{"key":"2026042206250814000_5.1.e002183.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026042206250814000_5.1.e002183.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02987-8"},{"key":"2026042206250814000_5.1.e002183.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01689-3"},{"key":"2026042206250814000_5.1.e002183.61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S2213-8587(22)00044-4","article-title":"Risks and burdens of incident diabetes in long COVID: a cohort study","volume":"10","author":"Xie","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026042206250814000_5.1.e002183.62","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2026042206250814000_5.1.e002183.63","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.64","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-087179","article-title":"Transparent reporting of observational studies emulating a target trial: the TARGET Statement","volume":"390","author":"Cashin","year":"2025","journal-title":"BMJ"},{"key":"2026042206250814000_5.1.e002183.65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026042206250814000_5.1.e002183.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2113319"},{"key":"2026042206250814000_5.1.e002183.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2026042206250814000_5.1.e002183.68","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01871"},{"key":"2026042206250814000_5.1.e002183.69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The Hazards of Hazard Ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026042206250814000_5.1.e002183.70","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/aje\/kwae361","article-title":"Why use methods that require proportional hazards?","volume":"194","author":"Stensrud","year":"2025","journal-title":"Am J Epidemiol"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-002183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:26:10Z","timestamp":1776875170000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjmed-2025-002183"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-002183","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}